Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Boehringer Ingelheim

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Boehringer Ingelheim's 2013 sales performance.

Boehringer Ingelheim GmbH

Merck, Bayer flesh out vericiguat heart failure data at ACC

Merck, Bayer flesh out vericiguat heart failure data at ACC

Some outstanding questions include where vericiguat lies in relation to the SGLT2 inhibitors such as Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga/Forxiga (dapagliflozin), which are also

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes Formally rejects extended use of SGLT2 inhibitor. The US Food and Drug Administration (FDA) has formally rejected Eli Lilly and Boehringer Ingelheim’s bid to extend the use of their SGLT2 ... Jardiance (empagliflozin) is already approved to treat type

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status and Boehringer Ingelheim’s Giotrif (afatinib), and also seem to resist cancer immunotherapies such as checkpoint inhibitors.

FDA clears wider use for Boehringer’s Ofev in lung disease

FDA clears wider use for Boehringer’s Ofev in lung disease Drug was first approved in 2014 for pulmonary fibrosis. Boehringer Ingelheim has snared another approval for its pulmonary fibrosis drug Ofev from the US Food and Drug Administration (FDA), this time ... Ofev is already a blockbuster seller for Boehringer

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout Boehringer Ingelheim took a different tack with its Alzheimer’s candidate BI 409306, which targeted PDE9, but that drug also failed mid-stage testing and was unable to show any improvement

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics